

## Exhibitor Presentation

# The Evolution of Drug Discovery Modalities Powered by Innovation and Convergence 1

JBA Drug Discovery Modality Study Group

Date : Wednesday, October 8, 2025, 15:30-16:45

Location : Pacifico Yokohama A Hall, A-42 JBA Booth

Showcasing cutting-edge challenges and solutions through diverse modalities, breakthrough technologies, and convergence—spotlighting startups and pioneers shaping the future of drug discovery.

15:30~15:45

### **New Drug Discovery Modalities: Harnessing Antibody–Nucleic Acid Conjugates**

Tsukasa Sugo (President and CEO, GenAhead Bio Inc.)

15:45~16:00

### **High-Performance Antibody Screening Enabled by the Integration of Single-Cell and Cell-Free Technologies**

Yo Amakusa (CEO, iBody Inc.)

16:00~16:15

### **iXgene's Challenge: Local High-Concentration iPS Cell Therapy for the Radical Cure of Intractable Cancers**

Atsushi Mizuno (COO, iXgene Inc.)

16:15~16:30

### **Advancing Antibody Drug Discovery (TBD)**

Tadashi Matsuura (CTO, Executive Officer, Perseus Proteomics Inc.)

16:30~16:45

### **From Target-Based Drug Discovery to ASO Therapeutics: Veritas In Silico's Dual Strategy in Small Molecules and ASOs, and a QbD-Driven Approach to Overcoming Nucleic Acid Drug Challenges**

Shingo Nakamura (President and CEO, Veritas In Silico Inc.)

## Exhibitor Presentation

# The Evolution of Drug Discovery Modalities Powered by Innovation and Convergence 2

JBA Drug Discovery Modality Study Group

Date : Thursday, October 9, 2025, 11:30-12:30

Location : Pacifico Yokohama A Hall, A-42 JBA Booth

Showcasing cutting-edge challenges and solutions through diverse modalities, breakthrough technologies, and convergence—spotlighting startups and pioneers shaping the future of drug discovery.

11:30~11:45

### Value Creation Through Automation

Takeshi Tanaka (Sales Department, RORZE Lifescience Inc.)

11:45~12:00

### Heteroduplex Oligonucleotide (HDO) as a Novel Drug Discovery Modality

Iwao Nozawa (Head of Business Development, Rena Therapeutics Inc.)

12:00~12:15

### Next-Generation Antibody Drug Development Utilizing VHH Antibodies

Hidekazu Masaki (Head of Business Development, Epsilon Molecular Engineering Inc.)

12:15~12:30

### Novel Modalities from Mycoplasma Glycolipid Research: A Global 'Preclinical-to-Clinical' Strategy

Kazuhiro Matsuda (President & CEO, M Bio Technology Inc. / Director, Mycoplasma Infection Research Center)

